XML 96 R80.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stockholders' Equity (Details)
12 Months Ended
Dec. 31, 2019
USD ($)
vote
$ / shares
shares
Dec. 31, 2018
USD ($)
$ / shares
shares
Dec. 31, 2007
demand_right
shares
Nov. 30, 2019
USD ($)
Class of Stock [Line Items]        
Preferred stock, shares authorized (in shares) 30,000,000 30,000,000    
Stock repurchase program, authorized amount | $       $ 1,000,000,000.0
Treasury stock, shares acquired (in shares) 722,596      
Cost of treasury stock shares received | $ $ 254,000,000.0      
Number of demand rights to require the company to conduct registered underwritten public offering | demand_right     3  
Class A Stock        
Class of Stock [Line Items]        
Common stock, shares authorized (in shares) 40,000,000 40,000,000    
Common stock, par value (in dollars per share) | $ / shares $ 0.001 $ 0.001    
Number of votes per share | vote 10      
Common Stock        
Class of Stock [Line Items]        
Common stock, shares authorized (in shares) 320,000,000 320,000,000    
Common stock, par value (in dollars per share) | $ / shares $ 0.001 $ 0.001    
Number of votes per share | vote 1      
Sanofi        
Class of Stock [Line Items]        
Number of shares of common stock purchased (in shares)     12,000,000  
Maximum percentage of outstanding shares that may be acquired, under 'standstill' provisions 30.00%      
Percentage of outstanding shares or voting rights under amended investor agreement 20.00%      
Percentage of outstanding shares that the Company is required to appoint an individual agreed upon by the Company and the Collaborator to the Company's board of directors 20.00%      
Sanofi Collaboration Agreement, Immuno-oncology        
Class of Stock [Line Items]        
Treasury stock, shares acquired (in shares) 210,733 215,387    
Cost of treasury stock shares received | $ $ 73,300,000 $ 75,800,000    
Maximum shares the collaborator could sell (in shares) 1,400,000      
Number of shares the collaborator available to sell (in shares) 869,828      
Bayer        
Class of Stock [Line Items]        
Maximum percentage of outstanding shares that may be acquired, under 'standstill' provisions 20.00%      
Teva        
Class of Stock [Line Items]        
Maximum percentage of outstanding shares that may be acquired, under 'standstill' provisions 5.00%